Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 Next > Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma June 05, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study June 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD RCUS Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA June 01, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis May 26, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conference May 25, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023 May 17, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Appoints Cindy Perettie Executive Vice President of Kite May 16, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera May 09, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV) May 04, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences May 01, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces First Quarter 2023 Financial Results April 27, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations April 16, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023 April 13, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities March 22, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma March 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 March 20, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD NRIX Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV February 22, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Completes Acquisition of Tmunity February 22, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients February 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies February 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer February 17, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 February 14, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia February 09, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer February 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend February 02, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results February 02, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer February 01, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences January 27, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023 January 19, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer January 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.